Evidence map›Paper›PMID 36561586›Full record

ArticleCureus2022

Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV.

Stephanie Boisclair, Amanda Brahim, Jose Sandoval-Sus

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Stephanie BoisclairInternal Medicine, Memorial Healthcare System, Pembroke Pines, USA.
Amanda BrahimHematology/Oncology Pharmacy, Memorial Cancer Institute, Pembroke Pines, USA.
Jose Sandoval-SusOncology and Hematology, Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, USA.
Masaryk Memorial Cancer Institute · CZMemorial Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is known to cause a rare form of leukemia/lymphoma called adult T-cell leukemia/lymphoma (ATLL). Although ATLL is known to have a high co-infection rate with human immunodeficiency virus (HIV) in areas where both viruses are endemic, clinical trials, such as the phase three trial for mogamulizumab, continue to exclude patients living with HIV. We here describe the utilization and therapeutic course of mogamulizumab for ATLL in a patient living with HIV. Unfortunately, due to exclusion of patients with co-viral infections in trials, decisions regarding clinical care in these patients remain challenging with the need to rely on retrospective publications for safety and efficacy.

Indexed as

adult t cell lymphomaclinical trial disparitieshivhtlv-1/2human immunodeficiency virushuman immunodeficiency virus infectionmogamulizumab

Identifiers

PMID36561586
PMCPMC9767665
OpenAlexW4309430854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.